- Mechanism
- Stimulates PI3K/AKT pathways and evades IGF binding proteins
- Route
- subcutaneous
- Half-life
- LR3: 20-30 hours | DES: 20-30 minutes
- Legal status
- Research Only
Overview
IGF-1 LR3 & DES are highly potent, synthetic variants of human insulin-like growth factor-1 engineered for increased biological activity. By bypassing standard binding protein regulation, the IGF-1 LR3 & DES peptide variants stimulate cellular hyperplasia and muscle hypertrophy far more effectively than endogenous IGF-1. Researchers study these compounds to understand their profound impact on metabolic regulation, accelerated tissue repair, and potential treatments for severe muscle wasting or growth deficiencies.
Potential Benefits
- Enhanced Muscle Hyperplasia: Research indicates these variants stimulate myoblast proliferation and muscle cell growth more potently than native IGF-1 (Pesall et al., 2001).
- Improved Metabolic Regulation: Studies in diabetic models show that potent IGF-1 variants can restore growth and regulate metabolism without inducing all characteristic insulin effects (Tomas et al., 1993).
- Accelerated Tissue Repair: By evading IGF binding proteins, these peptide variants deliver rapid, localized cellular repair and regeneration in damaged tissues.
- Targeted Fat Loss: These peptides promote lipolysis by forcing cells to utilize fatty acids for energy production during periods of caloric deficit.
- Enhanced Lactation Performance: Animal models demonstrate that Long-R3-IGF-I can enhance maternal lactation performance and alter mammary gene expression during prolonged lactation (Hadsell et al., 2008).
Where to Buy IGF-1 LR3 & DES
Research compound. IGF-1 LR3 & DES is a research chemical, typically not FDA-approved for human consumption. Sale or use for human consumption may be illegal in your jurisdiction.
No compensation. PeptideStack does not endorse, verify, or receive compensation from any vendor. No affiliate or referral relationships.
Verify third-party COAs and consult a qualified healthcare provider before using any compound.
Side Effects
Common side effects:
- Hypoglycemia (low blood sugar)
- Localized injection site reactions
- Water retention and mild edema
- Increased hunger and fatigue
- Joint or muscle aches
Rare or serious side effects:
- Organomegaly (enlargement of internal organs)
- Insulin resistance with prolonged use
- Potential acceleration of pre-existing tumor growth
- Severe hypoglycemic shock
IGF-1 LR3 & DES is not FDA-approved and is intended for research purposes only. Consult a qualified healthcare provider before use.
Mechanism of Action
Receptor activation and binding protein evasion drive the primary mechanism of the IGF-1 LR3 & DES peptide variants. Native IGF-1 is heavily regulated by insulin-like growth factor binding proteins (IGFBPs), which limit its bioavailability and half-life (Donnelly & Holly, 1996). IGF-1 LR3 contains an arginine substitution at position 3 and a 13-amino-acid extension, while IGF-1 DES lacks the first three amino acids at the N-terminus. These structural modifications drastically reduce their affinity for IGFBPs, allowing more free peptide to bind directly to the IGF-1 receptor.
Cellular proliferation and metabolic shifts occur rapidly following this receptor engagement. Once bound, these peptides activate the PI3K/AKT and MAPK pathways, which are critical for myoblast proliferation, protein synthesis, and cellular survival (Pesall et al., 2001). Furthermore, they induce a metabolic shift by inhibiting protein breakdown and promoting lipolysis, forcing cells to utilize fatty acids for energy. This dual action underpins the profound IGF-1 LR3 & DES benefits observed in research settings.
Origin & History
Synthetic development of IGF-1 variants began as researchers sought to overcome the extremely short half-life and rapid clearance of native human IGF-1. Scientists engineered IGF-1 LR3 and IGF-1 DES to resist degradation and binding by IGFBPs, thereby creating highly stable and potent analogs for laboratory use. Early studies demonstrated that these modifications could restore growth in diabetic animal models more effectively than standard IGF-1 (Tomas et al., 1993). These breakthroughs established the foundation for utilizing modified growth factors in cellular biology.
Current regulatory and research status restricts the IGF-1 LR3 & DES peptide strictly to in vitro and animal research applications. Neither variant has received approval from the FDA or other global regulatory bodies for human therapeutic use. Despite their lack of clinical approval, they remain vital tools in biotechnology for cell culture media and in preclinical studies investigating muscle wasting, metabolic disorders, and tissue regeneration.